DEF 14A: Lineage Cell Therapeutics Seeks Shareholder Approval for $6 Million Securities Issuance to Broadwood Partners

Lineage Cell Therapeutics is holding a special shareholder meeting to approve the issuance of common shares and warrants to Broadwood Partners, aiming to raise approximately $6 million.

Summary

• Lineage Cell Therapeutics is seeking shareholder approval for a proposed securities issuance to Broadwood Partners, L.P.
• The company aims to issue common shares and warrants to Broadwood, potentially raising approximately $6 million in gross proceeds.
• This issuance is part of a larger offering that already raised $24 million from other investors, bringing the total potential gross proceeds to $30 million.
• The shareholder meeting is scheduled for January 27, 2025, and the company needs approval to comply with NYSE American listing standards.
• If approved, the total gross proceeds from the offering could reach approximately $30 million, or $27.4 million after deducting fees, with an additional potential $36 million from warrant exercises.
• Broadwood Partners already owns 41,666,255 shares, representing 18.90% of the company, and this transaction could increase their ownership to 24.32% if all warrants are exercised.
• The company will use the net proceeds for working capital and general corporate purposes, including research and development.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it outlines a necessary capital raise, it also highlights potential dilution and increased control by a major shareholder. The language is factual and professional, without overly optimistic or pessimistic tones.

Positives

• The proposed securities issuance will provide Lineage with approximately $6 million in additional gross proceeds.
• The funds will be used for working capital, research and development, and general corporate purposes.
• The company has already raised $24 million from other investors in the same offering.
• The offering has been approved by the Pricing Committee and the Audit Committee of the Board.
• Broadwood Partners has agreed to vote in favor of the proposal, which could help ensure its approval.

Negatives

• The issuance of new shares will dilute the ownership interest of existing shareholders, excluding Broadwood.
• Broadwood Partners will increase its ownership stake and voting power, potentially influencing company decisions.
• Certain provisions in the warrants could deter a potential acquisition of Lineage by a third party.
• If the proposal is not approved, the company will need to hold additional shareholder meetings, incurring further expenses.
• The combined purchase price per share of the common shares and common warrants in the Offering was less than the minimum price as defined by NYSE American listing requirements.

Risks

• The issuance of new shares will dilute the ownership of existing shareholders.
• Broadwood Partners will gain increased influence over the company.
• The warrant terms could deter potential acquisitions.
• Failure to obtain shareholder approval will require additional meetings and expenses.
• Future sales of shares by Broadwood could negatively impact the market price of Lineage's stock.
• The company may not be able to raise the full $36 million from warrant exercises.

Future Outlook

The company expects to use the net proceeds from the sale and issuance of securities for working capital and general corporate purposes, including research and development expenses and capital expenditures. The company also expects to issue the common shares and common warrants under the SPA as soon as practicable after shareholder approval.

Management Comments

• Our board of directors recommends that you vote FOR all the proposals described in the accompanying proxy statement.
• The Audit Committee determined that the sale and issuance of the SPA securities pursuant to the SPA satisfied the foregoing.
• The Pricing Committee and the Audit Committee reviewed and considered all relevant information available to it about the Offering and the interests of Broadwood and Mr. Bradsher therein, including the purpose and the potential benefits to Lineage of the Offering and the terms of the SPA and related form of common warrant compared with terms of the securities purchase agreement and related form of common warrant for the other investors in the Offering, and determined that the Offering is advisable and in the best interests of our shareholders.

Industry Context

This announcement reflects a common practice for biotech companies to raise capital through securities offerings. The need for shareholder approval highlights the regulatory requirements for such transactions, particularly when involving significant ownership stakes and potential dilution. The involvement of a healthcare-focused institutional investor like Broadwood Partners is typical in the biotech sector.

Comparison to Industry Standards

• The use of a registered direct offering is a common method for biotech companies to raise capital, particularly when they need to access funds quickly.
• The combined purchase price of $0.76 per share and warrant is below the market value, which is not uncommon in such offerings, but requires shareholder approval under NYSE American rules.
• The terms of the warrants, including the exercise price and duration, are generally consistent with industry standards for similar transactions.
• The involvement of a significant shareholder like Broadwood Partners is not unusual, but the potential increase in their ownership stake and voting power is a key consideration for other shareholders.
• The use of a placement agent and the associated fees are standard practice in these types of offerings.

Related Party Transactions

• The proposed securities issuance to Broadwood Partners is considered a related party transaction due to Neal Bradsher's affiliation with both Lineage and Broadwood.

Stakeholder Impact

• Existing shareholders, excluding Broadwood, will experience dilution of their ownership interest.
• Broadwood Partners will increase its ownership stake and voting power.
• The company will have additional capital for operations and research and development.
• Potential investors may be deterred by the concentration of ownership and the warrant terms.

Next Steps

• Shareholders will vote on the proposals at the special meeting on January 27, 2025.
• If approved, the company will proceed with the issuance of securities to Broadwood Partners.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will file a Current Report on Form 8-K with the SEC within four business days after the Meeting to announce the final voting results.

Key Dates

Keywords

securities issuance, shareholder approval, common shares, warrants, Broadwood Partners, NYSE American, dilution, capital raise, proxy statement, registered direct offering